Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer and Metastasis Reviews
Published in: Cancer and Metastasis Reviews 3/2016

Open Access 01-09-2016 | CLINICAL

Telomeres and telomerase in head and neck squamous cell carcinoma: from pathogenesis to clinical implications

Authors: Paolo Boscolo-Rizzo, Maria Cristina Da Mosto, Enrica Rampazzo, Silvia Giunco, Annarosa Del Mistro, Anna Menegaldo, Lorena Baboci, Monica Mantovani, Giancarlo Tirelli, Anita De Rossi

Published in: Cancer and Metastasis Reviews | Issue 3/2016

Login to get access

Abstract

Strongly associated with tobacco use, heavy alcohol consumption, and with high-risk human papillomavirus (HPV) infection, head and neck squamous cell carcinoma (HNSCC) is a frequently lethal, heterogeneous disease whose pathogenesis is a multistep and multifactorial process involving genetic and epigenetic events. The majority of HNSCC patients present with locoregional advanced stage disease and are treated with combined modality strategies that can markedly impair quality of life and elicit unpredictable results. A large fraction of those who undergo locoregional treatment and achieve a complete response later develop locoregional recurrences or second field tumors. Biomarkers that are thus able to stratify risk and enable clinicians to tailor treatment plans and to personalize post-therapeutic surveillance strategies are highly desirable. To date, only HPV status is considered a reliable independent predictor of treatment response and survival in patients with HNSCC arising from the oropharyngeal site. Recent studies suggest that telomere attrition, which may be an early event in human carcinogenesis, and telomerase activation, which is detected in up to 90 % of malignancies, could be potential markers of cancer risk and disease outcome. This review examines the current state of knowledge on and discusses the implications linked to telomere dysfunction and telomerase activation in the development and clinical outcome of HNSCC.
Literature
1.
Ferlay, J., Steliarova-Foucher, E., Lortet-Tieulent, J., Rosso, S., Coebergh, J. W., Comber, H., et al. (2013). Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. European Journal of Cancer, 49, 1374–403.PubMedCrossRef
2.
Leemans, C. R., Braakhuis, B. J., & Brakenhoff, R. H. (2011). The molecular biology of head and neck cancer. Nature Reviews Cancer, 11, 9–22.PubMedCrossRef
3.
Gillison, M. L., Koch, W. M., Capone, R. B., Spafford, M., Westra, W. H., Wu, L., et al. (2000). Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. Journal of the National Cancer Institute, 92, 709–20.PubMedCrossRef
4.
Snijders, P. J., Cromme, F. V., van den Brule, A. J., Schrijnemakers, H. F., Snow, G. B., Meijer, C. J., et al. (1992). Prevalence and expression of human papillomavirus in tonsillar carcinomas, indicating a possible viral etiology. International Journal of Cancer, 51, 845–50.PubMedCrossRef
5.
Chaturvedi, A. K., Anderson, W. F., Lortet-Tieulent, J., Curado, M. P., Ferlay, J., Franceschi, S., et al. (2013). Worldwide trends in incidence rates for oral cavity and oropharyngeal cancers. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 31, 4550–9. doi:10.​1200/​JCO.​2013.​50.​3870.CrossRef
6.
Boscolo-Rizzo, P., Del Mistro, A., Bussu, F., Lupato, V., Baboci, L., Almadori, G., et al. (2013). New insights into human papillomavirus-associated head and neck squamous cell carcinoma. Acta Otorhinolaryngol Ital Organo Uff Della Soc Ital Otorinolaringol E Chir Cerv-Facc, 33, 77–87.
7.
Baboci, L., Holzinger, D., Boscolo-Rizzo, P., Tirelli, G., Spinato, R., Lupato, V., et al. (2016). Low prevalence of HPV-driven head and neck squamous cell carcinoma in North-East Italy. Papillomavirus Research, 2, 133–40. doi:10.​1016/​j.​pvr.​2016.​07.​002.CrossRef
8.
Andl, T., Kahn, T., Pfuhl, A., Nicola, T., Erber, R., Conradt, C., et al. (1998). Etiological involvement of oncogenic human papillomavirus in tonsillar squamous cell carcinomas lacking retinoblastoma cell cycle control. Cancer Research, 58, 5–13.PubMed
9.
Braakhuis, B. J. M., Snijders, P. J. F., Keune, W.-J. H., Meijer, C. J. L. M., Ruijter-Schippers, H. J., Leemans, C. R., et al. (2004). Genetic patterns in head and neck cancers that contain or lack transcriptionally active human papillomavirus. Journal of the National Cancer Institute, 96, 998–1006.PubMedCrossRef
10.
Jung, A. C., Briolat, J., Millon, R., de Reyniès, A., Rickman, D., Thomas, E., et al. (2010). Biological and clinical relevance of transcriptionally active human papillomavirus (HPV) infection in oropharynx squamous cell carcinoma. International Journal of Cancer, 126, 1882–94. doi:10.​1002/​ijc.​24911.PubMed
11.
Lindquist, D., Romanitan, M., Hammarstedt, L., Näsman, A., Dahlstrand, H., Lindholm, J., et al. (2007). Human papillomavirus is a favourable prognostic factor in tonsillar cancer and its oncogenic role is supported by the expression of E6 and E7. Molecular Oncology, 1, 350–5. doi:10.​1016/​j.​molonc.​2007.​08.​005.PubMedCrossRef
12.
van Houten, V. M., Snijders, P. J., van den Brekel, M. W., Kummer, J. A., Meijer, C. J., van Leeuwen, B., et al. (2001). Biological evidence that human papillomaviruses are etiologically involved in a subgroup of head and neck squamous cell carcinomas. International Journal of Cancer, 93, 232–5. doi:10.​1002/​ijc.​1313.PubMedCrossRef
13.
Wiest, T., Schwarz, E., Enders, C., Flechtenmacher, C., & Bosch, F. X. (2002). Involvement of intact HPV16 E6/E7 gene expression in head and neck cancers with unaltered p53 status and perturbed pRb cell cycle control. Oncogene, 21, 1510–7. doi:10.​1038/​sj.​onc.​1205214.PubMedCrossRef
14.
15.
16.
Boscolo-Rizzo, P., Gava, A., Marchiori, C., Baggio, V., & Da Mosto, M. C. (2011). Functional organ preservation in patients with locoregionally advanced head and neck squamous cell carcinoma treated by platinum-based multidrug induction chemotherapy and concurrent chemoradiotherapy. Annals of Oncology: Official Journal of the European Society of Medical Oncology ESMO, 22, 1894–901. doi:10.​1093/​annonc/​mdq681.CrossRef
17.
Boscolo-Rizzo, P., Gava, A., Baggio, V., Marchiori, C., Stellin, M., Fuson, R., et al. (2011). Matched survival analysis in patients with locoregionally advanced resectable oropharyngeal carcinoma: platinum-based induction and concurrent chemoradiotherapy versus primary surgical resection. International Journal of Radiation Oncology, Biology, Physics, 80, 154–60. doi:10.​1016/​j.​ijrobp.​2010.​01.​032.PubMedCrossRef
18.
19.
Vermorken, J. B., & Specenier, P. (2010). Optimal treatment for recurrent/metastatic head and neck cancer. Annals of Oncology: Official Journal of the European Society of Medical Oncology ESMO, 21 Suppl 7, vii252–61. doi:10.​1093/​annonc/​mdq453.
20.
Griffioen, G. H. M. J., Louie, A. V., de Bree, R., Smit, E. F., Paul, M. A., Slotman, B. J., et al. (2015). Second primary lung cancers following a diagnosis of primary head and neck cancer. Lung Cancer Amsterdam Netherlands, 88, 94–9. doi:10.​1016/​j.​lungcan.​2015.​01.​011.CrossRef
21.
Vermorken, J. B., Mesia, R., Rivera, F., Remenar, E., Kawecki, A., Rottey, S., et al. (2008). Platinum-based chemotherapy plus cetuximab in head and neck cancer. The New England Journal of Medicine, 359, 1116–27. doi:10.​1056/​NEJMoa0802656.PubMedCrossRef
22.
Vermorken, J. B., Remenar, E., van Herpen, C., Gorlia, T., Mesia, R., Degardin, M., et al. (2007). Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. The New England Journal of Medicine, 357, 1695–704.PubMedCrossRef
23.
Bourhis, J., Overgaard, J., Audry, H., Ang, K. K., Saunders, M., Bernier, J., et al. (2006). Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis. Lancet, 368, 843–54.PubMedCrossRef
24.
Pignon, J. P., le Maitre, A., Maillard, E., Bourhis, J., & Group, M.-N. C. (2009). Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiotherapy & Oncology, Journal of the European Society for Therapeutic Radiology and Oncology, 92, 4–14.CrossRef
25.
Ang, K. K., Harris, J., Wheeler, R., Weber, R., Rosenthal, D. I., Nguyen-Tan, P. F., et al. (2010). Human papillomavirus and survival of patients with oropharyngeal cancer. The New England Journal of Medicine, 363, 24–35.PubMedPubMedCentralCrossRef
26.
27.
28.
Chung, C. H., Parker, J. S., Karaca, G., Wu, J., Funkhouser, W. K., Moore, D., et al. (2004). Molecular classification of head and neck squamous cell carcinomas using patterns of gene expression. Cancer Cell, 5, 489–500.PubMedCrossRef
29.
Sakr, W. A., Gale, N., Gnepp, D. R., & Crissman, J. D. (2009). Chapter 1—squamous intraepithelial neoplasia of the upper aerodigestive tract. Diagn. Surg. Pathol. Head Neck (Secondth ed., pp. 1–44). Philadelphia: W.B. Saunders.
30.
31.
32.
Zhang, L., & Rosin, M. P. (2001). Loss of heterozygosity: a potential tool in management of oral premalignant lesions? Journal of Oral Pathology & Medicine; Official Publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology, 30, 513–20.CrossRef
33.
Ha, P. K., Pilkington, T. A., Westra, W. H., Sciubba, J., Sidransky, D., & Califano, J. A. (2002). Progression of microsatellite instability from premalignant lesions to tumors of the head and neck. International Journal of Cancer, 102, 615–7. doi:10.​1002/​ijc.​10748.PubMedCrossRef
34.
Partridge, M., Emilion, G., Pateromichelakis, S., A’Hern, R., Phillips, E., & Langdon, J. (1998). Allelic imbalance at chromosomal loci implicated in the pathogenesis of oral precancer, cumulative loss and its relationship with progression to cancer. Oral Oncology, 34, 77–83.PubMedCrossRef
35.
Slaughter, D. P., Southwick, H. W., & Smejkal, W. (1953). Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin. Cancer, 6, 963–8.PubMedCrossRef
36.
37.
38.
van Houten, V. M. M., Tabor, M. P., van den Brekel, M. W. M., Kummer, J. A., Denkers, F., Dijkstra, J., et al. (2002). Mutated p53 as a molecular marker for the diagnosis of head and neck cancer. The Journal of Pathology, 198, 476–86. doi:10.​1002/​path.​1242.PubMedCrossRef
39.
Roesch-Ely, M., Nees, M., Karsai, S., Ruess, A., Bogumil, R., Warnken, U., et al. (2007). Proteomic analysis reveals successive aberrations in protein expression from healthy mucosa to invasive head and neck cancer. Oncogene, 26, 54–64. doi:10.​1038/​sj.​onc.​1209770.PubMedCrossRef
40.
Ausoni, S., Boscolo-Rizzo, P., Singh, B., Da Mosto, M. C., Spinato, G., Tirelli, G., et al. (2016). Targeting cellular and molecular drivers of head and neck squamous cell carcinoma: current options and emerging perspectives. Cancer Metastasis Reviews. doi:10.​1007/​s10555-016-9625-1.PubMed
41.
Stransky, N., Egloff, A. M., Tward, A. D., Kostic, A. D., Cibulskis, K., Sivachenko, A., et al. (2011). The mutational landscape of head and neck squamous cell carcinoma. Science, 333, 1157–60.PubMedPubMedCentralCrossRef
42.
Network, C. G. A. (2015). Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature, 517, 576–82.CrossRef
43.
Agrawal, N., Frederick, M. J., Pickering, C. R., Bettegowda, C., Chang, K., Li, R. J., et al. (2011). Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science, 333, 1154–7.PubMedPubMedCentralCrossRef
44.
Killela, P. J., Reitman, Z. J., Jiao, Y., Bettegowda, C., Agrawal, N., Diaz, L. A., et al. (2013). TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proceedings of the National Academy of Sciences, 110, 6021–6. doi:10.​1073/​pnas.​1303607110.CrossRef
45.
Vinothkumar, V., Arunkumar, G., Revathidevi, S., Arun, K., Manikandan, M., Rao, A. K. D. M., et al. (2015). TERT promoter hot spot mutations are frequent in Indian cervical and oral squamous cell carcinomas. Tumour Biology : The Journal of the International Society for Oncodevelopmental Biology and Medicine. doi:10.​1007/​s13277-015-4694-2.
46.
Qu, Y., Dang, S., Wu, K., Shao, Y., Yang, Q., Ji, M., et al. (2014). TERT promoter mutations predict worse survival in laryngeal cancer patients. International Journal of Cancer, 135, 1008–10.PubMedCrossRef
47.
Kandoth, C., McLellan, M. D., Vandin, F., Ye, K., Niu, B., Lu, C., et al. (2013). Mutational landscape and significance across 12 major cancer types. Nature, 502, 333–9.PubMedPubMedCentralCrossRef
48.
49.
50.
Wichmann, G., Rosolowski, M., Krohn, K., Kreuz, M., Boehm, A., Reiche, A., et al. (2015). The role of HPV RNA transcription, immune response-related gene expression and disruptive TP53 mutations in diagnostic and prognostic profiling of head and neck cancer. International Journal of Cancer, 137, 2846–57. doi:10.​1002/​ijc.​29649.PubMedCrossRef
51.
52.
Hanken, H., Gröbe, A., Cachovan, G., Smeets, R., Simon, R., Sauter, G., et al. (2014). CCND1 amplification and cyclin D1 immunohistochemical expression in head and neck squamous cell carcinomas. Clinical Oral Investigations, 18, 269–76. doi:10.​1007/​s00784-013-0967-6.PubMedCrossRef
53.
Liu, X., Dakic, A., Zhang, Y., Dai, Y., Chen, R., & Schlegel, R. (2009). HPV E6 protein interacts physically and functionally with the cellular telomerase complex. Proceedings of the National Academy of Sciences, 106, 18780–5. doi:10.​1073/​pnas.​0906357106.CrossRef
54.
55.
Karatzanis, A. D., Koudounarakis, E., Papadakis, I., & Velegrakis, G. (2012). Molecular pathways of lymphangiogenesis and lymph node metastasis in head and neck cancer. European Archives of Oto-Rhino-Laryngol: Official Journal of European Federation of Oto-Rhino-Laryngol Societies EUFOS: Affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, 269, 731–7. doi:10.​1007/​s00405-011-1809-2.
56.
57.
58.
59.
60.
Fernandez-Marcelo, T., Gomez, A., Pascua, I., de Juan, C., Head, J., Hernando, F., et al. (2015). Telomere length and telomerase activity in non-small cell lung cancer prognosis: clinical usefulness of a specific telomere status. Journal of Experimental & Clinical Cancer Research , 34, 78. doi:10.​1186/​s13046-015-0195-9.CrossRef
61.
Downey, M. G., Going, J. J., Stuart, R. C., & Keith, W. N. (2001). Expression of telomerase RNA in oesophageal and oral cancer. Journal of Oral Pathology & Medicine, 30, 577–81.CrossRef
62.
63.
Boscolo-Rizzo, P., Rampazzo, E., Perissinotto, E., Piano, M. A., Giunco, S., Baboci, L., et al. (2015). Telomere shortening in mucosa surrounding the tumor: biosensor of field cancerization and prognostic marker of mucosal failure in head and neck squamous cell carcinoma. Oral Oncology, 51, 500–7. doi:10.​1016/​j.​oraloncology.​2015.​02.​100.PubMedCrossRef
64.
Aida, J., Izumo, T., Shimomura, N., Nakamura, K., Ishikawa, N., Matsuura, M., et al. (2010). Telomere lengths in the oral epithelia with and without carcinoma. European Journal of Cancer, 46, 430–8.PubMedCrossRef
65.
66.
67.
68.
69.
70.
71.
72.
Fumagalli, M., Rossiello, F., Clerici, M., Barozzi, S., Cittaro, D., Kaplunov, J. M., et al. (2012). Telomeric DNA damage is irreparable and causes persistent DNA-damage-response activation. Nature Cell Biology, 14, 355–65. doi:10.​1038/​ncb2466.PubMedPubMedCentralCrossRef
73.
74.
75.
Banin, S., Moyal, L., Shieh, S., Taya, Y., Anderson, C. W., Chessa, L., et al. (1998). Enhanced phosphorylation of p53 by ATM in response to DNA damage. Science, 281, 1674–7.PubMedCrossRef
76.
Herbig, U., Jobling, W. A., Chen, B. P. C., Chen, D. J., & Sedivy, J. M. (2004). Telomere shortening triggers senescence of human cells through a pathway involving ATM, p53, and p21CIP1, but not p16INK4a. Molecular Cell, 14, 501–13. doi:10.​1016/​S1097-2765(04)00256-4.PubMedCrossRef
77.
78.
79.
80.
81.
Nakamura, T. M., Morin, G. B., Chapman, K. B., Weinrich, S. L., Andrews, W. H., Lingner, J., et al. (1997). Telomerase catalytic subunit homologs from fission yeast and human. Science, 277, 955–9.PubMedCrossRef
82.
83.
84.
Smogorzewska, A., van Steensel, B., Bianchi, A., Oelmann, S., Schaefer, M. R., Schnapp, G., et al. (2000). Control of human telomere length by TRF1 and TRF2. Molecular and Cellular Biology, 20, 1659–68.PubMedPubMedCentralCrossRef
85.
86.
Xu, D., Wang, Q., Gruber, A., Björkholm, M., Chen, Z., Zaid, A., et al. (2000). Downregulation of telomerase reverse transcriptase mRNA expression by wild type p53 in human tumor cells. Oncogene, 19, 5123–33. doi:10.​1038/​sj.​onc.​1203890.PubMedCrossRef
87.
88.
Kanzawa, T., Komata, T., Kyo, S., Germano, I. M., Kondo, Y., & Kondo, S. (2003). Down-regulation of telomerase activity in malignant glioma cells by p27KIP1. International Journal of Oncology, 23, 1703–8.PubMed
89.
Akiyama, M., Hideshima, T., Hayashi, T., Tai, Y.-T., Mitsiades, C. S., Mitsiades, N., et al. (2003). Nuclear factor-kappaB p65 mediates tumor necrosis factor alpha-induced nuclear translocation of telomerase reverse transcriptase protein. Cancer Research, 63, 18–21.PubMed
90.
91.
92.
Saretzki, G. (2014). Extra-telomeric functions of human telomerase: cancer, mitochondria and oxidative stress. Current Pharmaceutical Design, 20, 6386–403.PubMedCrossRef
93.
Liu, Z., Li, Q., Li, K., Chen, L., Li, W., Hou, M., et al. (2013). Telomerase reverse transcriptase promotes epithelial-mesenchymal transition and stem cell-like traits in cancer cells. Oncogene, 32, 4203–13. doi:10.​1038/​onc.​2012.​441.PubMedCrossRef
94.
Ding, D., Xi, P., Zhou, J., Wang, M., & Cong, Y.-S. (2013). Human telomerase reverse transcriptase regulates MMP expression independently of telomerase activity via NF-kB-dependent transcription. The FASEB Journal: Official Publication of the Federal American Society of Experimental Biology, 27, 4375–83. doi:10.​1096/​fj.​13-230904.CrossRef
95.
96.
Episkopou, H., Draskovic, I., Van Beneden, A., Tilman, G., Mattiussi, M., Gobin, M., et al. (2014). Alternative lengthening of telomeres is characterized by reduced compaction of telomeric chromatin. Nucleic Acids Research, 42, 4391–405. doi:10.​1093/​nar/​gku114.PubMedPubMedCentralCrossRef
97.
98.
Härle-Bachor, C., & Boukamp, P. (1996). Telomerase activity in the regenerative basal layer of the epidermis inhuman skin and in immortal and carcinoma-derived skin keratinocytes. Proceedings of the National Academy of Sciences of the United States of America, 93, 6476–81.PubMedPubMedCentralCrossRef
99.
Choudhury, A. R., Ju, Z., Djojosubroto, M. W., Schienke, A., Lechel, A., Schaetzlein, S., et al. (2007). Cdkn1a deletion improves stem cell function and lifespan of mice with dysfunctional telomeres without accelerating cancer formation. Nature Genetics, 39, 99–105. doi:10.​1038/​ng1937.PubMedCrossRef
100.
101.
Crowe, D. L., Nguyen, D. C., & Ohannessian, A. (2005). Mechanism of telomerase repression during terminal differentiation of normal epithelial cells and squamous carcinoma lines. International Journal of Oncology, 27, 847–54.PubMed
102.
103.
104.
105.
Ernst, A., Jones, D. T. W., Maass, K. K., Rode, A., Deeg, K. I., Jebaraj, B. M. C., et al. (2016). Telomere dysfunction and chromothripsis. International Journal of Cancer, 138, 2905–14. doi:10.​1002/​ijc.​30033.PubMedCrossRef
106.
Gordon, K. E., Ireland, H., Roberts, M., Steeghs, K., McCaul, J. A., MacDonald, D. G., et al. (2003). High levels of telomere dysfunction bestow a selective disadvantage during the progression of human oral squamous cell carcinoma. Cancer Research, 63, 458–67.PubMed
107.
Gisselsson, D., Jonson, T., Yu, C., Martins, C., Mandahl, N., Wiegant, J., et al. (2002). Centrosomal abnormalities, multipolar mitoses, and chromosomal instability in head and neck tumours with dysfunctional telomeres. British Journal of Cancer, 87, 202–7. doi:10.​1038/​sj.​bjc.​6600438.PubMedPubMedCentralCrossRef
108.
109.
Artandi, S. E., Chang, S., Lee, S. L., Alson, S., Gottlieb, G. J., Chin, L., et al. (2000). Telomere dysfunction promotes non-reciprocal translocations and epithelial cancers in mice. Nature, 406, 641–5. doi:10.​1038/​35020592.PubMedCrossRef
110.
Aida, J., Kobayashi, T., Saku, T., Yamaguchi, M., Shimomura, N., Nakamura, K., et al. (2012). Short telomeres in an oral precancerous lesion: Q-FISH analysis of leukoplakia. Journal of Oral Pathology & Medicine, 41, 372–8.CrossRef
111.
Meeker, A. K., Hicks, J. L., Iacobuzio-Donahue, C. A., Montgomery, E. A., Westra, W. H., Chan, T. Y., et al. (2004). Telomere length abnormalities occur early in the initiation of epithelial carcinogenesis. Clinical Cancer Research, 10, 3317–26.PubMedCrossRef
112.
Kammori, M., Poon, S. S. S., Nakamura, K.-I., Izumiyama, N., Ishikawa, N., Kobayashi, M., et al. (2007). Squamous cell carcinomas of the esophagus arise from a telomere-shortened epithelial field. International Journal of Molecular Medicine, 20, 793–9.PubMed
113.
Heaphy, C. M., Gaonkar, G., Peskoe, S. B., Joshu, C. E., De Marzo, A. M., Lucia, M. S., et al. (2015). Prostate stromal cell telomere shortening is associated with risk of prostate cancer in the placebo arm of the Prostate Cancer Prevention Trial. The Prostate, 75, 1160–6. doi:10.​1002/​pros.​22997.PubMedPubMedCentralCrossRef
114.
Hong, S.-M., Heaphy, C. M., Shi, C., Eo, S.-H., Cho, H., Meeker, A. K., et al. (2011). Telomeres are shortened in acinar-to-ductal metaplasia lesions associated with pancreatic intraepithelial neoplasia but not in isolated acinar-to-ductal metaplasias. Modern Pathology: Official Journal of the United States and Canadian Academy of Pathology Inc, 24, 256–66. doi:10.​1038/​modpathol.​2010.​181.CrossRef
115.
Pickering, C. R., Zhang, J., Yoo, S. Y., Bengtsson, L., Moorthy, S., Neskey, D. M., et al. (2013). Integrative genomic characterization of oral squamous cell carcinoma identifies frequent somatic drivers. Cancer Discovery, 3, 770–81.PubMedCrossRef
116.
117.
Braakhuis, B. J. M., Tabor, M. P., Kummer, J. A., Leemans, C. R., & Brakenhoff, R. H. (2003). A genetic explanation of Slaughter’s concept of field cancerization: evidence and clinical implications. Cancer Research, 63, 1727–30.PubMed
118.
Nakamura, K.-I., Izumiyama-Shimomura, N., Sawabe, M., Arai, T., Aoyagi, Y., Fujiwara, M., et al. (2002). Comparative analysis of telomere lengths and erosion with age in human epidermis and lingual epithelium. The Journal of Investigative Dermatology, 119, 1014–9. doi:10.​1046/​j.​1523-1747.​2002.​19523.​x.PubMedCrossRef
119.
Kang, M. K., Guo, W., & Park, N. H. (1998). Replicative senescence of normal human oral keratinocytes is associated with the loss of telomerase activity without shortening of telomeres. Cell Growth & Differentiation: The Molecular Biology Journal of the American Association for Cancer Research, 9, 85–95.
120.
Fujimoto, R., Kamata, N., Yokoyama, K., Ueda, N., Satomura, K., Hayashi, E., et al. (2001). Expression of telomerase components in oral keratinocytes and squamous cell carcinomas. Oral Oncology, 37, 132–40.PubMedCrossRef
121.
Kilian, A., Bowtell, D. D. L., Abud, H. E., Hime, G. R., Venter, D. J., Keese, P. K., et al. (1997). Isolation of a candidate human telomerase catalytic subunit gene, which reveals complex splicing patterns in different cell types. Human Molecular Genetics, 6, 2011–9. doi:10.​1093/​hmg/​6.​12.​2011.PubMedCrossRef
122.
Luzar, B., Poljak, M., Marin, I. J., & Gale, N. (2003). Telomerase reactivation is an early event in laryngeal carcinogenesis. Modern Pathology, 16, 841–8.PubMedCrossRef
123.
Liao, J., Mitsuyasu, T., Yamane, K., & Ohishi, M. (2000). Telomerase activity in oral and maxillofacial tumors. Oral Oncology, 36, 347–52.PubMedCrossRef
124.
Liao, C. T., Chen, I. H., Chang, J. T., Wang, H. M., Hsieh, L. L., & Cheng, A. J. (2003). Lack of correlation of betel nut chewing, tobacco smoking, and alcohol consumption with telomerase activity and the severity of oral cancer. Chang Gung Medical Journal, 26, 637–45.PubMed
125.
Liao, C. T., Chang, J. T.-C., Wang, H. M., Chen, I. H., Lin, C. Y., Chen, T. M., et al. (2004). Telomerase as an independent prognostic factor in head and neck squamous cell carcinoma. Head & Neck, 26, 504–12.CrossRef
126.
Kunicka, Z., Mucha, I., & Fajkus, J. (2008). Telomerase activity in head and neck cancer. Anticancer Research, 28, 3125–9.PubMed
127.
Chen, M., Yang, B., & Zhang, X. (2008). Effects of telomerase activity on carcinogenesis and survival in laryngeal carcinoma. The Journal of International Medical Research, 36, 336–42.PubMedCrossRef
128.
Curran, A. J., Gullane, P. J., Irish, J., Macmillan, C., Freeman, J., & Kamel-Reid, S. (2000). Telomerase activity is upregulated in laryngeal squamous cell carcinoma. Laryngoscope, 110, 391–6.PubMedCrossRef
129.
Chang, L. Y., Lin, S. C., Chang, C. S., Wong, Y. K., Hu, Y. C., & Chang, K. W. (1999). Telomerase activity and in situ telomerase RNA expression in oral carcinogenesis. Journal of Oral Pathology & Medicine, 28, 389–96.CrossRef
130.
Fabricius, E. M., Gurr, U., & Wildner, G. P. (2002). Telomerase activity levels in the surgical margin and tumour distant tissue of the squamous cell carcinoma of the head-and-neck. Analytical Cellular Pathology, 24, 25–39.PubMedPubMedCentralCrossRef
131.
Hohaus, S., Cavallo, S., Bellacosa, A., Genuardi, M., Galli, J., Cadoni, G., et al. (1996). Telomerase activity in human laryngeal squamous cell carcinomas. Clinical Cancer Research, 2, 1895–900.PubMed
132.
Yajima, Y., Noma, H., Furuya, Y., Nomura, T., Yamauchi, T., Kasahara, K., et al. (2004). Quantification of telomerase activity of regions unstained with iodine solution that surround oral squamous cell carcinoma. Oral Oncology, 40, 314–20.PubMedCrossRef
133.
Patel, M. M., Patel, D. D., Parekh, L. J., Raval, G. N., Rawal, R. M., Bhatavdekar, J. M., et al. (1999). Evaluation of telomerase activation in head and neck cancer. Oral Oncology, 35, 510–5.PubMedCrossRef
134.
Mutirangura, A., Supiyaphun, P., Trirekapan, S., Sriuranpong, V., Sakuntabhai, A., Yenrudi, S., et al. (1996). Telomerase activity in oral leukoplakia and head and neck squamous cell carcinoma. Cancer Research, 56, 3530–3.PubMed
135.
Califano, J., Ahrendt, S. A., Meininger, G., Westra, W. H., Koch, W. M., & Sidransky, D. (1996). Detection of telomerase activity in oral rinses from head and neck squamous cell carcinoma patients. Cancer Research, 56, 5720–2.PubMed
136.
Fabricius, E. M., Kruse-Boitschenko, U., Khoury, R., Wildner, G. P., Raguse, J. D., & Klein, M. (2009). Immunohistochemical determination of the appropriate anti-hTERT antibodies for in situ detection of telomerase activity in frozen sections of head and neck squamous cell carcinomas and tumor margin tissues. International Journal of Oncology, 34, 1257–79.PubMed
137.
Sumida, T., Sogawa, K., Hamakawa, H., Sugita, A., Tanioka, H., & Ueda, N. (1998). Detection of telomerase activity in oral lesions. Journal of Oral Pathology & Medicine, 27, 111–5.CrossRef
138.
Mao, L., El-Naggar, A. K., Fan, Y. H., Lee, J. S., Lippman, S. M., Kayser, S., et al. (1996). Telomerase activity in head and neck squamous cell carcinoma and adjacent tissues. Cancer Research, 56, 5600–4.PubMed
139.
Koscielny, S., Eggeling, F., Dahse, R., & Fiedler, W. (2004). The influence of reactivation of the telomerase in tumour tissue on the prognosis of squamous cell carcinomas in the head and neck. Journal of Oral Pathology & Medicine, 33, 538–42.CrossRef
140.
Lee, B. K., Diebel, E., Neukam, F. W., Wiltfang, J., & Ries, J. (2001). Diagnostic and prognostic relevance of expression of human telomerase subunits in oral cancer. International Journal of Oncology, 19, 1063–8.PubMed
141.
Fiedler, M., Ressler, S., Campo-Fernandez, B., Laich, A., Jansen, L., Widschwendter, A., et al. (2005). Expression of the high-risk human papillomavirus type 18 and 45 E7 oncoproteins in cervical carcinoma biopsies. The Journal of General Virology, 86, 3235–41.PubMedCrossRef
142.
Curran, A. J., Denis, K. S., Irish, J., Gullane, P. J., MacMillan, C., & Kamel-Reid, S. (1998). Telomerase activity in oral squamous cell carcinoma. Archives of Otolaryngology – Head & Neck Surgery, 124, 784–8.CrossRef
143.
Kannan, S., Tahara, H., Yokozaki, H., Mathew, B., Nalinakumari, K. R., Nair, M. K., et al. (1997). Telomerase activity in premalignant and malignant lesions of human oral mucosa. Cancer Epidemiology, Biomarkers & Prevention, 6, 413–20.
144.
Ogawa, Y., Nishioka, A., Hamada, N., Terashima, M., Inomata, T., Yoshida, S., et al. (1998). Changes in telomerase activity of advanced cancers of oral cavity and oropharynx during radiation therapy: correlation with clinical outcome. International Journal of Molecular Medicine, 2, 301–7.PubMed
145.
Miyoshi, Y., Tsukinoki, K., Imaizumi, T., Yamada, Y., Ishizaki, T., Watanabe, Y., et al. (1999). Telomerase activity in oral cancer. Oral Oncology, 35, 283–9.PubMedCrossRef
146.
Fujita, H., Nagata, M., Hoshina, H., Nagashima, K., Seki, Y., Tanaka, K., et al. (2004). Clinical significance and usefulness of quantification of telomerase activity in oral malignant and nonmalignant lesions. International Journal of Oral and Maxillofacial Surgery, 33, 693–9.PubMedCrossRef
147.
Soria, J. C., Morat, L., Commo, F., Dabit, D., Perie, S., Sabatier, L., et al. (2001). Telomerase activation cooperates with inactivation of p16 in early head and neck tumorigenesis. British Journal of Cancer, 84, 504–11.PubMedPubMedCentralCrossRef
148.
Sainger, R. N., Shah, F. D., Telang, S. D., Shah, P. M., & Patel, P. S. (2009). Telomere attrition and telomerase activity are associated with GSTM1 polymorphism in oral cancer. Cancer Biomarkers, 5, 189–95.PubMed
149.
Liu, Y., Dong, X. L., Tian, C., & Liu, H. G. (2012). Human telomerase RNA component (hTERC) gene amplification detected by FISH in precancerous lesions and carcinoma of the larynx. Diagnostic Pathology, 7, 34.PubMedPubMedCentralCrossRef
150.
Chiba K, Johnson JZ, Vogan JM, Wagner T, Boyle JM, Hockemeyer D. Cancer-associated TERT promoter mutations abrogate telomerase silencing. eLife 2015;4. doi:10.​7554/​eLife.​07918.
151.
Hayes, D. N., Van Waes, C., & Seiwert, T. Y. (2015). Genetic landscape of human papillomavirus-associated head and neck cancer and comparison to tobacco-related tumors. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, 33, 3227–34. doi:10.​1200/​JCO.​2015.​62.​1086.CrossRef
152.
153.
154.
Greenberg, R. A., O’Hagan, R. C., Deng, H., Xiao, Q., Hann, S. R., Adams, R. R., et al. (1999). Telomerase reverse transcriptase gene is a direct target of c-Myc but is not functionally equivalent in cellular transformation. Oncogene, 18, 1219–26. doi:10.​1038/​sj.​onc.​1202669.PubMedCrossRef
155.
Gewin, L., Myers, H., Kiyono, T., & Galloway, D. A. (2004). Identification of a novel telomerase repressor that interacts with the human papillomavirus type-16 E6/E6-AP complex. Genes & Development, 18, 2269–82. doi:10.​1101/​gad.​1214704.CrossRef
156.
Terrin, L., Dal Col, J., Rampazzo, E., Zancai, P., Pedrotti, M., Ammirabile, G., et al. (2008). Latent membrane protein 1 of Epstein-Barr virus activates the hTERT promoter and enhances telomerase activity in B lymphocytes. Journal of Virology, 82, 10175–87. doi:10.​1128/​JVI.​00321-08.PubMedPubMedCentralCrossRef
157.
Yang, L., Xu, Z., Liu, L., Luo, X., Lu, J., Sun, L., et al. (2014). Targeting EBV-LMP1 DNAzyme enhances radiosensitivity of nasopharyngeal carcinoma cells by inhibiting telomerase activity. Cancer Biology & Therapy, 15, 61–8. doi:10.​4161/​cbt.​26606.CrossRef
158.
159.
160.
161.
Murakami, J., Asaumi, J., Kawai, N., Tsujigiwa, H., Yanagi, Y., Nagatsuka, H., et al. (2005). Effects of histone deacetylase inhibitor FR901228 on the expression level of telomerase reverse transcriptase in oral cancer. Cancer Chemotherapy and Pharmacology, 56, 22–8. doi:10.​1007/​s00280-004-0976-x.PubMedCrossRef
162.
163.
Chang, J. T., Lu, Y.-C., Chen, Y.-J., Tseng, C.-P., Chen, Y.-L., Fang, C.-W., et al. (2006). hTERT phosphorylation by PKC is essential for telomerase holoprotein integrity and enzyme activity in head neck cancer cells. British Journal of Cancer, 94, 870–8. doi:10.​1038/​sj.​bjc.​6603008.PubMedPubMedCentralCrossRef
164.
165.
Luzar, B., Poljak, M., Marin, I. J., Eberlinc, A., Klopcic, U., & Gale, N. (2004). Human telomerase catalytic subunit gene re-expression is an early event in oral carcinogenesis. Histopathology, 45, 13–9.PubMedCrossRef
166.
Chrysovergis, A., Gorgoulis, V. G., Giotakis, I., Tsiambas, E., Karameris, A., Kittas, C., et al. (2011). Simultaneous over activation of EGFR, telomerase (h TERT), and cyclin D1 correlates with advanced disease in larynx squamous cell carcinoma: a tissue microarray analysis. Medical Oncology, 28, 871–7.PubMedCrossRef
167.
Sharma, H., Sen, S., Mathur, M., Bahadur, S., & Singh, N. (2004). Combined evaluation of expression of telomerase, survivin, and anti-apoptotic Bcl-2 family members in relation to loss of differentiation and apoptosis in human head and neck cancers. Head & Neck, 26, 733–40.CrossRef
168.
Kumar, S. K., Zain, R. B., Ismail, S. M., & Cheong, S. C. (2005). Human telomerase reverse transcriptase expression in oral carcinogenesis—a preliminary report. Journal of Experimental & Clinical Cancer Research, 24, 639–46.
169.
Luzar, B., Poljak, M., Marin, I. J., Fischinger, J., & Gale, N. (2001). Quantitative measurement of telomerase catalytic subunit (hTERT) mRNA in laryngeal squamous cell carcinomas. Anticancer Research, 21, 4011–5.PubMed
170.
Thurnher, D., Knerer, B., Formanek, M., & Kornfehl, J. (1998). Non-radioactive semiquantitative testing for the expression levels of telomerase activity in head and neck squamous cell carcinomas may be indicative for biological tumour behaviour. Acta Oto-Laryngologica, 118, 423–7.PubMedCrossRef
171.
Chen, H. H., Yu, C. H., Wang, J. T., Liu, B. Y., Wang, Y. P., Sun, A., et al. (2007). Expression of human telomerase reverse transcriptase (hTERT) protein is significantly associated with the progression, recurrence and prognosis of oral squamous cell carcinoma in Taiwan. Oral Oncology, 43, 122–9.PubMedCrossRef
172.
Freier, K., Pungs, S., Flechtenmacher, C., Bosch, F. X., Lichter, P., Joos, S., et al. (2007). Frequent high telomerase reverse transcriptase expression in primary oral squamous cell carcinoma. Journal of Oral Pathology & Medicine, 36, 267–72.CrossRef
173.
Samny, T. E., Halaby, H. E., Fiky, L. E., Nassar, M., Makhzangy, A. E., & Eissa, S. (2005). Prognostic value of telomerase and DNA ploidy in laryngeal carcinoma. European Archives of Oto-Rhino-Laryngology, 262, 799–803.PubMedCrossRef
174.
Eissa, S., Kenawy, G., Moteleb, F. A., El-Makhzangyc, A. N., & Nassar, M. (2005). Real-time PCR hTERT mRNA pattern in tumor core, edge, resection margin, and lymph nodes in laryngeal tumors: relation to proliferative index and impact on prognosis. Clinical Biochemistry, 38, 873–8.PubMedCrossRef
175.
Pannone, G., Maria, S. D., Zamparese, R., Metafora, S., Serpico, R., Morelli, F., et al. (2007). Prognostic value of human telomerase reverse transcriptase gene expression in oral carcinogenesis. International Journal of Oncology, 30, 1349–57.PubMed
176.
Patel, M. M., Parekh, L. J., Jha, F. P., Sainger, R. N., Patel, J. B., Patel, D. D., et al. (2002). Clinical usefulness of telomerase activation and telomere length in head and neck cancer. Head & Neck, 24, 1060–7.CrossRef
177.
Luzar, B., Poljak, M., Fischinger, J., Klopcic, U., & Gale, N. (2005). Telomerase catalytic subunit gene expression does not influence survival of patients with squamous cell carcinoma of the larynx and hypopharynx: a case–control study. The Journal of Laryngology and Otology, 119, 917–21.PubMedCrossRef
178.
Poremba, C., Heine, B., Diallo, R., Heinecke, A., Wai, D., Schaefer, K.-L., et al. (2002). Telomerase as a prognostic marker in breast cancer: high-throughput tissue microarray analysis of hTERT and hTR. The Journal of Pathology, 198, 181–9. doi:10.​1002/​path.​1191.PubMedCrossRef
179.
Bantis, A., Patsouris, E., Gonidi, M., Kavantzas, N., Tsipis, A., Athanassiadou, A.-M., et al. (2009). Telomerase RNA expression and DNA ploidy as prognostic markers of prostate carcinomas. Tumori, 95, 744–52.PubMed
180.
181.
182.
Artandi, S. E., Alson, S., Tietze, M. K., Sharpless, N. E., Ye, S., Greenberg, R. A., et al. (2002). Constitutive telomerase expression promotes mammary carcinomas in aging mice. Proceedings of the National Academy of Sciences of the United States of America, 99, 8191–6. doi:10.​1073/​pnas.​112515399.PubMedPubMedCentralCrossRef
183.
Yang, J., Wei, D., Wang, W., Shen, B., Xu, S., & Cao, Y. (2015). TRAF4 enhances oral squamous cell carcinoma cell growth, invasion and migration by Wnt-β-catenin signaling pathway. International Journal of Clinical and Experimental Pathology, 8, 11837–46.PubMedPubMedCentral
184.
Iwai, S., Yonekawa, A., Harada, C., Hamada, M., Katagiri, W., Nakazawa, M., et al. (2010). Involvement of the Wnt-β-catenin pathway in invasion and migration of oral squamous carcinoma cells. International Journal of Oncology, 37, 1095–103.PubMedCrossRef
185.
186.
Smalley, M. J., & Dale, T. C. (1999). Wnt signalling in mammalian development and cancer. Cancer Metastasis Reviews, 18, 215–30.PubMedCrossRef
187.
188.
Zhao, T., Hu, F., Qiao, B., Chen, Z., & Tao, Q. (2015). Telomerase reverse transcriptase potentially promotes the progression of oral squamous cell carcinoma through induction of epithelial-mesenchymal transition. International Journal of Oncology, 46, 2205–15. doi:10.​3892/​ijo.​2015.​2927.PubMed
189.
Loercher, A., Lee, T. L., Ricker, J. L., Howard, A., Geoghegen, J., Chen, Z., et al. (2004). Nuclear factor-kappaB is an important modulator of the altered gene expression profile and malignant phenotype in squamous cell carcinoma. Cancer Research, 64, 6511–23. doi:10.​1158/​0008-5472.​CAN-04-0852.PubMedCrossRef
190.
Allen, C. T., Ricker, J. L., Chen, Z., & Van Waes, C. (2007). Role of activated nuclear factor-kB in the pathogenesis and therapy of squamous cell carcinoma of the head and neck. Head & Neck, 29, 959–71. doi:10.​1002/​hed.​20615.CrossRef
191.
Ghosh, A., Saginc, G., Leow, S. C., Khattar, E., Shin, E. M., Yan, T. D., et al. (2012). Telomerase directly regulates NF-kB-dependent transcription. Nature Cell Biology, 14, 1270–81. doi:10.​1038/​ncb2621.PubMedCrossRef
192.
Zhang, R.-L., Peng, L.-X., Yang, J.-P., Zheng, L.-S., Xie, P., Wang, M.-Y., et al. (2016). IL-8 suppresses E-cadherin expression in nasopharyngeal carcinoma cells by enhancing E-cadherin promoter DNA methylation. International Journal of Oncology, 48, 207–14. doi:10.​3892/​ijo.​2015.​3226.PubMed
193.
194.
Yu, L., Mu, Y., Sa, N., Wang, H., & Xu, W. (2014). Tumor necrosis factor α induces epithelial-mesenchymal transition and promotes metastasis via NF-kB signaling pathway-mediated TWIST expression in hypopharyngeal cancer. Oncology Reports, 31, 321–7. doi:10.​3892/​or.​2013.​2841.PubMed
195.
196.
197.
198.
199.
200.
Hou, L., Savage, S. A., Blaser, M. J., Perez-Perez, G., Hoxha, M., Dioni, L., et al. (2009). Telomere length in peripheral leukocyte DNA and gastric cancer risk. Cancer Epidemiology, Biomarkers & Prevention: A Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology, 18, 3103–9. doi:10.​1158/​1055-9965.​EPI-09-0347.CrossRef
201.
Liu, Z., Ma, H., Wei, S., Li, G., Sturgis, E. M., & Wei, Q. (2011). Telomere length and TERT functional polymorphisms are not associated with risk of squamous cell carcinoma of the head and neck. Cancer Epidemiology, Biomarkers & Prevention: A Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology, 20, 2642–5. doi:10.​1158/​1055-9965.​EPI-11-0890.CrossRef
202.
Bau, D.-T., Lippman, S. M., Xu, E., Gong, Y., Lee, J. J., Wu, X., et al. (2013). Short telomere lengths in peripheral blood leukocytes are associated with an increased risk of oral premalignant lesion and oral squamous cell carcinoma. Cancer, 119, 4277–83. doi:10.​1002/​cncr.​28367.PubMedCrossRef
203.
204.
Wu, X., Amos, C. I., Zhu, Y., Zhao, H., Grossman, B. H., Shay, J. W., et al. (2003). Telomere dysfunction: a potential cancer predisposition factor. Journal of the National Cancer Institute, 95, 1211–8.PubMedCrossRef
205.
206.
207.
Hong DY, Lee BJ, Lee JC, Choi JS, Wang SG, Ro JH. Expression of VEGF, HGF, IL-6, IL-8, MMP-9, telomerase in peripheral blood of patients with head and neck squamous cell carcinoma 2009; 2:186–92.
208.
Terrin, L., Rampazzo, E., Pucciarelli, S., Agostini, M., Bertorelle, R., Esposito, G., et al. (2008). Relationship between tumor and plasma levels of hTERT mRNA in patients with colorectal cancer: implications for monitoring of neoplastic disease. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 14, 7444–51. doi:10.​1158/​1078-0432.​CCR-08-0478.CrossRef
209.
March-Villalba, J. A., Martínez-Jabaloyas, J. M., Herrero, M. J., Santamaria, J., Aliño, S. F., & Dasí, F. (2012). Cell-free circulating plasma hTERT mRNA is a useful marker for prostate cancer diagnosis and is associated with poor prognosis tumor characteristics. PLoS One, 7, e43470. doi:10.​1371/​journal.​pone.​0043470.PubMedPubMedCentralCrossRef
210.
Kang, Y., Zhang, J., Sun, P., & Shang, J. (2012). Circulating cell-free human telomerase reverse transcriptase mRNA in plasma and its potential diagnostic and prognostic value for gastric cancer. International Journal of Clinical Oncology, 18, 478–86. doi:10.​1007/​s10147-012-0405-9.PubMedCrossRef
211.
Li, Y. R., Wu, J. M., Wang, L., Huang, X., Shi, J., & Hu, L. H. (2005). Human telomerase reverse transcriptase expression and its clinical significance in laryngeal squamous cell carcinoma. Acta Oto-Laryngologica, 125, 409–14.PubMedCrossRef
Metadata
Title
Telomeres and telomerase in head and neck squamous cell carcinoma: from pathogenesis to clinical implications
Authors
Paolo Boscolo-Rizzo
Maria Cristina Da Mosto
Enrica Rampazzo
Silvia Giunco
Annarosa Del Mistro
Anna Menegaldo
Lorena Baboci
Monica Mantovani
Giancarlo Tirelli
Anita De Rossi
Publication date
01-09-2016
Publisher
Springer US
Published in
Cancer and Metastasis Reviews / Issue 3/2016
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI
https://doi.org/10.1007/s10555-016-9633-1

Other articles of this Issue 3/2016

Cancer and Metastasis Reviews 3/2016 Go to the issue

NON-THEMATIC REVIEW

The roles and implications of exosomes in sarcoma

CLINICAL

Tissue engineering and regenerative medicine in musculoskeletal oncology

Retraction Note

Retraction Note: Targeted immune therapy of ovarian cancer

CLINICAL

Estrogen, progesterone, and HER2/neu receptor discordance between primary and metastatic breast tumours—a review

NON-THEMATIC REVIEW

Origins, structures, and functions of circulating DNA in oncology

CLINICAL

Second- and third-line systemic therapy in patients with advanced esophagogastric cancer: a systematic review of the literature
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits